AlphAIAlphAI — Financial news for AI agents
investing.comOCT 52 min read$VSTM

Verastem stock maintained at Buy by BTIG ahead of data readout

BTIG maintained a Buy rating and $18.00 price target on Verastem (VSTM) ahead of a data presentation on October 14. The stock is currently trading at $7.80, with a Strong Buy analyst consensus. Verastem reported Q2 2026 revenue of $40.07M, exceeding expectations. The company is developing KRAS G12D inhibitor VS-7375 for various cancers, with phase 1/2 data expected soon.

Original reporting
investing.com
Published Oct 5, 2026, 1:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$VSTM
Bullish
high confidence
Mentioned
$VSTM
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VSTMBullishMed
01

Why it matters

Earnings beat reinforces bullish analyst stance, but upcoming trial data adds uncertainty.

02

Market read

Strong Q2 results and continued analyst support suggest near-term upside, tempered by pending trial data.

03

What to watch

Potential regulatory delays for VS-7375 could temper upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst firm BTIG and others reiterated Buy ratings ahead of a Phase 1/2 data readout for Verastem's KRAS G12D inhibitor.

Company-level read

Ticker impact

$VSTMBullishHigh confidence
Context

Verastem posted Q2 2026 results beating revenue and loss expectations, and analysts reiterated Buy ratings with higher price targets.

Expected impact

likely upward pressure as the market prices in the earnings beat and raised guidance

Evidence & confidence

Revenue of $40.07M vs $23.09M estimate and narrower loss per share suggest improved fundamentals, prompting analysts to maintain bullish stance.

Market effects

Sector

Positive earnings may lift other biotech stocks focused on KRAS inhibitors.

Regional

US biotech sector could see modest gains.

Global

Limited to US-listed biotech investors.

Counterpoint

What could challenge this read

Despite the beat, the upcoming data readout adds risk; the stock may be overbought.

Key entities

  • Company
    Verastem

    Biotech firm developing KRAS G12D inhibitor VS-7375.

  • Analyst
    BTIG

    Equity research firm reiterating Buy rating.

Read at source← All news

Related articles

OCT 5
$VSTMMedAI 8/10

Verastem shares get Buy rating reiterated by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating on Verastem (VSTM) with a $18.00 price target, citing positive clinical data for avutometinib plus defactinib in ovarian cancer. The stock trades at $7.70, with a Strong Buy consensus. Verastem reported a narrower-than-expected Q2 2026 loss and revenue exceeding forecasts, driven by product sales and a license payment. Cantor Fitzgerald also reiterated an Overweight rating.

investing.com2 min
OCT 2
$VSTMHighAI 9/10

Verastem presents new data on ovarian cancer drug combination

Verastem Oncology presented data from its Phase 2 RAMP 201 trial, showing positive results for its drug combination in treating recurrent low-grade serous ovarian cancer. The combination achieved objective response rates of 22% and 18% in specific patient groups, with median progression-free survival of 13 months. The FDA approved the combination in May 2025, pending confirmatory trial results. The data was presented at the International Gynecologic Cancer Society Annual Global Meeting.

investing.com2 min
AUG 20
$VSTMHighAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

aol.com3 min
AUG 14
$VSTMMedAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

fool.com14 min
AUG 7
$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

sci-tech-today.com6 min